Share on LinkedInShare on LinkedIn

ARTICLE · 05 DECEMBER 2012

Why Innovators Need A Right Of Appeal In PM(NOC) Applications

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

McCarthy Tétrault LLP provides a broad range of legal services, delivering strategic and...

View firm profile
Explore more from McCarthy Tétrault

COMBIGAN is an ophthalmic drug marketed in Canada by Allergan. It is useful for lowering pressure in the eye and treating glaucoma.

CanadaIntellectual Property

On Friday, November 23, 2012 the Federal Court of Appeal released its decision in A-312-12 dismissing Apotex's appeal of Justice Hughes' order dated June 18, 2012 granting Allergan's application for a prohibition order in respect of the drug COMBIGAN. This decision, and related litigation involving COMBIGAN, clearly demonstrates why innovators need a right of appeal when unsuccessful in applications they bring pursuant to section 6 of the PM(NOC) Regulations.

Facts and Issues

COMBIGAN is an ophthalmic drug marketed in Canada by Allergan. It is useful for lowering pressure in the eye and treating glaucoma.

The first generic to seek early market entry for a generic version of COMBIGAN was Sandoz. Of particular importance, Sandoz alleged that the invention claimed in Canadian Patent Number 2,440,764 (the '764 Patent) was obvious and therefore the claims were invalid. Allergan commenced an application seeking an order prohibiting the Minister of Health from issuing

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from